1012 GMT [Dow Jones] KBC Peel Hunt upgrades Vectura Group (VEC.LN) to buy from hold following the drug maker's decision to seek partners to help it develop generic asthma medicine VR315 in the US. Analyst Paul Cuddon says the company previously indicated it wanted to go it alone after European partner Novartis (NOVN.VX) pulled out, but securing a partner will likely enable Vectura to cut VR315 development costs and should increase the product's chances of successfully getting to market. Target price rise to 70p from 45p. Shares flat at 38p. (
[email protected]) Contact us in London. +44-20-7842-9464
[email protected] (END) Dow Jones Newswires June 08, 2010 06:12 ET (10:12 GMT)